Michelle Goonasekera

University of Oxford

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Collaborators (10)

David Preiss

University of Oxford

UNITED KINGDOM

View details

Nuwan Jayawickreme

Professor of Psychology

Touro College

UNITED STATES

View details

Isla Mackenzie

Academic, Clinical Professor (Teaching and Research) of Cardiovascular Medicine

University of Dundee

UNITED KINGDOM

View details

Farah E Latif

Clinical Lecturer

Cardiff University

UNITED KINGDOM

View details

Sawako Kato

Nagoya University Hospital

JAPAN

View details

David F. Keane

IRELAND

View details

Laura Blackie

University of Nottingham

UNITED KINGDOM

View details

Johannes Stegbauer

University Hospital Düsseldorf

GERMANY

View details

Mark Segal

University of Florida

UNITED STATES

View details

Kaitlin Mayne

Clinical Lecturer in Renal Medicine

University of Glasgow

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michelle Goonasekera

Research Interests

Explore related searches

Contact this professor

Articles (10)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD

Accuracy of heart failure ascertainment using routinely collected healthcare data: a systematic review and meta-analysis.

Design, recruitment and baseline characteristics of the LENS trial.

Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

Empagliflozin in Patients with Chronic Kidney Disease.

Knowing when someone is resilient: Development and validation of a measure of adaptive functioning among war-affected Sri Lankan Tamils

Collaborators (10)

David Preiss

Nuwan Jayawickreme

Isla Mackenzie

Farah E Latif

Sawako Kato

David F. Keane

Laura Blackie

Johannes Stegbauer

Mark Segal

Kaitlin Mayne

Make your next move.